In December 2014 Volcano Corporation was acquired by Royal Phillips NV for US$1.2 billion. Formerly doing business as Volcano Pharmaceuticals and having outgrown SBIR eligibility , Volcano Corporation organized around development, manufacture and commercialization of a broad suite of intravascular ultrasound, or IVUS, and functional measurement, or FM, products that enhance the diagnosis and treatment of vascular and structural heart disease. Its IVUS products include consoles, single-procedure disposable catheters, and advanced functionality options. Other products include In-Vision Gold, an intravascular ultrasound system for patient imaging; the s5 Imaging System, designed to meet diagnostic and imaging needs; Eagle Eye Gold, an imaging catheter; Visions PV 018, designed for visualization of peripheral vessels; IVUS VH, used to read and interpret IVUS images with color-coded identification of plaque types; R100, a reusable pullback device; and Avanar Fix, an imaging catheter. Before its own acquisition by Royal Philips NV in late 2014, Volcano had acquired six smaller entities andcreated working relationship with a wide cross section of players - large and small - across their own and abutting space.
